BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 37326792)

  • 1. Baricitinib: A Review in Severe Alopecia Areata.
    Fung S; Shirley M
    Am J Clin Dermatol; 2023 Jul; 24(4):661-668. PubMed ID: 37326792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two Phase 3 Trials of Baricitinib for Alopecia Areata.
    King B; Ohyama M; Kwon O; Zlotogorski A; Ko J; Mesinkovska NA; Hordinsky M; Dutronc Y; Wu WS; McCollam J; Chiasserini C; Yu G; Stanley S; Holzwarth K; DeLozier AM; Sinclair R;
    N Engl J Med; 2022 May; 386(18):1687-1699. PubMed ID: 35334197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
    Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
    Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.
    Senna M; Mostaghimi A; Ohyama M; Sinclair R; Dutronc Y; Wu WS; Yu G; Chiasserini C; Somani N; Holzwarth K; King B
    J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):583-593. PubMed ID: 38391212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.
    Ko JM; Mayo TT; Bergfeld WF; Dutronc Y; Yu G; Ball SG; Somani N; Craiglow BG
    JAMA Dermatol; 2023 Sep; 159(9):970-976. PubMed ID: 37556146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials.
    King B; Shapiro J; Ohyama M; Egeberg A; Piraccini BM; Craiglow B; Sinclair R; Chen YF; Wu WS; Ding Y; Somani N; Dutronc Y
    Br J Dermatol; 2023 Nov; 189(6):666-673. PubMed ID: 37708254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olumiant
    Gupta AK; Wang T; Vincent K; Abramovits W
    Skinmed; 2022; 20(6):452-455. PubMed ID: 36537681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
    King B; Ko J; Forman S; Ohyama M; Mesinkovska N; Yu G; McCollam J; Gamalo M; Janes J; Edson-Heredia E; Holzwarth K; Dutronc Y
    J Am Acad Dermatol; 2021 Oct; 85(4):847-853. PubMed ID: 34090959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baricitinib as the first systemic treatment for severe alopecia areata.
    Kincaid CM; Arnold JD; Mesinkovska NA
    Expert Rev Clin Immunol; 2023 Jun; 19(6):565-573. PubMed ID: 37042112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review.
    Egeberg A; Linsell L; Johansson E; Durand F; Yu G; Vañó-Galván S
    Dermatol Ther (Heidelb); 2023 Dec; 13(12):2951-2991. PubMed ID: 37833617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus Kinase Inhibitors in the Treatment of Alopecia Areata.
    Stefanis AJ
    Prague Med Rep; 2023; 124(1):5-15. PubMed ID: 36763827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.
    King B; Mostaghimi A; Shimomura Y; Zlotogorski A; Choi GS; Blume-Peytavi U; Passeron T; Holzwarth K; Dutronc Y; McCollam J; Yang FE; Stanley S; Wu WS; Sinclair R
    Br J Dermatol; 2023 Feb; 188(2):218-227. PubMed ID: 36763878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baricitinib for the Treatment of Alopecia Areata.
    Freitas E; Guttman-Yassky E; Torres T
    Drugs; 2023 Jun; 83(9):761-770. PubMed ID: 37195491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus kinase inhibitors for alopecia areata: A narrative review.
    Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
    Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Janus kinase inhibitors for the treatment of alopecia areata].
    Kobal I; Ramot Y
    Hautarzt; 2022 May; 73(5):336-343. PubMed ID: 35482047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of Baricitinib in the Treatment of Alopecia Areata.
    Singh R; Driscoll MS
    J Drugs Dermatol; 2023 Sep; 22(9):935-940. PubMed ID: 37683061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Baricitinib Restores Hair Loss in Alopecia Areata.
    Slomski A
    JAMA; 2022 Jun; 327(24):2386. PubMed ID: 35762995
    [No Abstract]   [Full Text] [Related]  

  • 19. Janus kinase inhibitors for alopecia areata.
    King BA; Craiglow BG
    J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System.
    Song CJ; Riley CA; Wilkison BD; Cho S
    Mil Med; 2024 Jun; ():. PubMed ID: 38850223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.